832735-60-1 Usage
General Description
7-Bromo[1,2,4]triazolo[4,3-a]pyridine is a chemical compound with the molecular formula C5H3BrN4. It is a heterocyclic compound containing a triazolopyridine ring system with a bromine substituent at the 7-position. 7-Bromo[1,2,4]triazolo[4,3-a]pyridine has potential applications in the field of medicinal chemistry and drug discovery due to its unique structure and biological activities. It may be used in the synthesis of new pharmaceutical compounds or as a building block in organic synthesis. Additionally, 7-Bromo[1,2,4]triazolo[4,3-a]pyridine may also have potential biological activities that make it of interest for further research and development in various scientific fields.
Check Digit Verification of cas no
The CAS Registry Mumber 832735-60-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,3,2,7,3 and 5 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 832735-60:
(8*8)+(7*3)+(6*2)+(5*7)+(4*3)+(3*5)+(2*6)+(1*0)=171
171 % 10 = 1
So 832735-60-1 is a valid CAS Registry Number.
InChI:InChI=1/C6H4BrN3/c7-5-1-2-10-4-8-9-6(10)3-5/h1-4H
832735-60-1Relevant articles and documents
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF
-
, (2015/07/07)
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.
CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
-
Page/Page column 71, (2010/08/18)
This invention relates to novel compounds of the Formula Formulas (I), (Ia1-20), (Ib1-20), (Ic1-20), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
